- UHRA Home
- Browsing by Author
Browsing by Author "Folkes, L.K."
Now showing items 1-4 of 4
-
Halogenated indole-3-acetic acids as oxidatively activated prodrugs with potential for targeted cancer therapy
Rossiter, S.; Folkes, L.K.; Wardman, P. (2002) -
Horseradish peroxidase-mediated gene therapy : choice of prodrugs in oxic and anoxic tumor conditions
Greco, O.; Rossiter, S.; Kanthou, C.; Folkes, L.K.; Wardman, P.; Tozer, G.M.; Dachs, G.U. (2001) -
A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas
Meyer, T.; Gaya, A.M.; Dancey, G.; Stratford, M.R.L.; Othman, S.; Sharma, S.; Wellsted, D.; Taylor, N.J.; Stirling, J.J.; Poupard, L.; Folkes, L.K.; Chan, P.S.; Pedley, R.B.; Chester, K.A.; Owen, K.; Violet, J.A.; Malaroda, A.; Green, A.J.; Buscombe, J.; Padhani, A.R.; Rustin, G.J.; Begent, R.H. (2009)Purpose: In preclinical models, radioimmunotherapy with 131I-A5B7 anti–carcinoembryonic antigen (CEA) antibody (131I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike ... -
Reactivity toward thiols and cytotoxicity of 3-methylene-2-oxindoles, cytotoxins from indole-3-acetic acids, on activation by peroxidases
Folkes, L.K.; Rossiter, S.; Wardman, P. (2002)